Skip to main content

Galapagos Will Use siRNA Vectors to Help Dutch Partners Develop Tx for Spinal Disorders

NEW YORK, Sept. 14 (GenomeWeb News) - Galapagos will help Amsterdam Molecular Therapeutics, the Netherlands Institute for Brain Research, and the Vrije Universiteit Amsterdam develop treatments for acute spinal cord and peripheral nerve damage, the company said today.


The collaboration, funded in part by a2 million ($2.5 million) grant from the Dutch government organization Senter, aims to develop drugs that promote nerve regeneration and reduce the effect of neural scarring, Galapagos said.


Terms of the deal call for the Dutch company to provide access to its siRNA vectors on a fee-for-service basis. It is hoped that access to this technology will enable the partners to "discover protein targets involved in regeneration of injured nerve tissue."


Once these targets have been identified, Amsterdam Molecular Therapeutics will develop technologies based on their gene therapy platform. The Netherlands Institute for Brain Research, meantime, will use its expertise in neuroregeneration and microarray technology and the Vrije Universiteit Amsterdam will analyze nerve cell growth to further develop the therapeutics, according to Galapagos.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.